Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 8—August 2024
Dispatch

Macrolide-Resistant Mycoplasma pneumoniae Infections among Children before and during COVID-19 Pandemic, Taiwan, 2017–2023

Tsung-Hua Wu, Yu-Ping Fang, Fang-Ching Liu, Hui-Hsien Pan, Yu-Ying Yang, Chiah-Sing Song, and Chun-Yi LeeComments to Author 
Author affiliations: Show Chwan Memorial Hospital, Changhua, Taiwan (T.-H. Wu, Y.-Y. Yang); College of Medicine, National Chung Hsing University, Taichung, Taiwan (T.-H. Wu, C.-Y. Lee); Chang Bing Show Chwan Memorial Hospital, Changhua (Y.-P. Fang, C.-S. Song, C.-Y Lee); Jen-Ai Hospital, Taichung (F.-C. Liu); Taichung Veterans General Hospital, Taichung (H.-H. Pan)

Main Article

Figure 1

Dynamic distribution of macrolide-resistant Mycoplasma pneumoniae infections among children before and during the COVID-19 pandemic, Taiwan, 2017–2023. A) M. pneumoniae infections were detected throughout the year, primarily from March to August. An M. pneumoniae outbreak occurred during 2017–2018. The M. pneumoniae detection rate substantially declined during the COVID-19 pandemic, 2021–2022. Light gray background represents 770 IgM-positive participants; dark gray background represents 209 cases confirmed by culture and PCR. Blue shading indicates timeframe of nonpharmaceutical interventions during the COVID-19 pandemic. B) Among 211 isolates, macrolide resistance was observed in 74 (35.1%) isolates. The resistance rate was 12.5% in 2017, increased to 48.3% in 2018 and to 62.5% in 2019, and reached 85.7% in 2020. Subsequently, the rate decreased to 18.2% in 2021 and dropped to 0% in 2022 and 2023.

Figure 1. Dynamic distribution of macrolide-resistant Mycoplasma pneumoniae infections among children before and during the COVID-19 pandemic, Taiwan, 2017–2023. A) M. pneumoniae infections were detected throughout the year, primarily from March to August. An M. pneumoniae outbreak occurred during 2017–2018. The M. pneumoniae detection rate substantially declined during the COVID-19 pandemic, 2021–2022. Light gray background represents 770 IgM-positive participants; dark gray background represents 209 cases confirmed by culture and PCR. Blue shading indicates timeframe of nonpharmaceutical interventions during the COVID-19 pandemic. B) Among 211 isolates, macrolide resistance was observed in 74 (35.1%) isolates. The resistance rate was 12.5% in 2017, increased to 48.3% in 2018 and to 62.5% in 2019, and reached 85.7% in 2020. Subsequently, the rate decreased to 18.2% in 2021 and dropped to 0% in 2022 and 2023.

Main Article

Page created: June 24, 2024
Page updated: July 21, 2024
Page reviewed: July 21, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external